Research Article

Macrophage Deficiency Makes Intestinal Epithelial Cells Susceptible to NSAID-Induced Damage

Xinxin Wang,1 Jiayang Wang,2 Tianyu Xie,1 Shuo Li,1 Di Wu,1 Yixun Lu,1 Xin Guo,1 and Lin Chen1

1Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Rd. Beijing 100853, China
2Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

Correspondence should be addressed to Lin Chen; chenlin850111@163.com

Xinxin Wang and Jiayang Wang contributed equally to this work.

Received 3 February 2020; Revised 31 August 2020; Accepted 29 September 2020; Published 17 November 2020

Academic Editor: Benoit Stijlemans

Copyright © 2020 Xinxin Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. In Crohn’s disease (CD), the mechanisms underlying the regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of mucosal barrier function in the ileum are unclear. We analyzed the molecular mechanisms underlying the regulation by GM-CSF of the mucosal barrier function.

Methods. We examined the role of GM-CSF in the intestinal barrier function in CD at the molecular-, cellular-, and animal-model levels.

Results. Macrophages directly secreted GM-CSF, promoting intestinal epithelial proliferation and inhibiting apoptosis, which maintained intestinal barrier function. Macrophages were absent in NSAID-induced ileitis, causing GM-CSF deficiency, increasing the apoptosis rate, decreasing the proliferation rate, increasing inter- and paracellular permeabilities, decreasing the TJP levels, and reducing the numbers of mesenteric lymph nodes, memory T cells, and regulatory T cells in Csf1lop/lop transgenic mice.

Conclusions. GM-CSF is required for the maintenance of intestinal barrier function. Macrophages directly secrete GM-CSF, promoting intestinal epithelial proliferation and inhibiting apoptosis.

1. Introduction

Crohn’s disease (CD) is a chronic, recurrent, insidious, and nonspecific transmural inflammation of the digestive tract. Its symptoms include digestive tract obstruction, perforation, abdominal abscess, fistula, and hemorrhage. Prolonged CD may cause psychiatric symptoms such as anxiety or depression, as well as localized malignancy. CD is a lifelong disease caused by interactions between genetic and environmental factors [1, 2]. However, the etiology and pathogenesis of CD are unclear.

More than 70 genes and loci are related to the occurrence and development of CD according to genome-wide association studies. NOD2/CARD15 was the first CD susceptibility gene to be discovered by genome-wide association studies. Although functional deletion of CARD15 increases the susceptibility to CD [3, 4], the explicit rate is low. CARD15-knockout mice do not spontaneously develop enterocolitis, suggesting that other factors contribute to the development of CD [5, 6].

Although nonsteroidal anti-inflammatory drug (NSAID-) induced gut barrier dysfunction and clinical relapse occur in patients with CD, the mechanisms are unclear [7, 8]. In addition, the level of granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibodies is significantly increased in patients with CD [9]. We reported that NSAID-associated intestinal barrier dysfunction may be correlated with GM-CSF autoantibodies, thereby promoting the activation of T cells and development of localized ileal CD [9, 10]. Therefore, GM-CSF is necessary to maintain ileal barrier function.

However, the molecular mechanisms underlying GM-CSF regulation of mucosal barrier function in the ileum are unclear. Therefore, we performed an animal study to evaluate...
the role of GM-CSF in intestinal barrier function in CD at the molecular, cellular, and animal-model levels.

2. Materials and Methods

2.1. Reagents. The following monoclonal antibodies were used: neutralizing anti-mouse CSF1 receptor (AFS98 [IgG2a]; S-I Nishikawa; RIKEN Center for Developmental Biology, Kobe, Japan), neutralizing anti-mouse GM-CSF (22E9.11; IgG2a; J. Abrams; DNAX, Palo Alto, CA), and neutralizing anti-mouse CSF1 and an IgG2a isotype control (F. Dodeller; MorphoSys, Munich, Germany) (35).

2.2. Mice. C57BL/6 mice were obtained from WEHI, Kew (VIC, Australia). GMCSF2/2 (29) and Csf1r-EGFP (Mac-Green) mice (36), backcrossed onto the C57BL/6 background, were bred in our on-site animal facility. BALB/c mice were obtained from the Animal Resource Centre (Perth, Australia). Mice (8–12 weeks old) were fed standard rodent chow and water ad libitum and were housed in sawdust-lined cages in groups of five. The study was approved by the Animal Experimentation Ethics Committee of The University of Melbourne and was conducted in compliance with the animal experimentation guidelines of the National Health and Medical Research Council of Australia.

2.3. Adoptive Cell Transfer. Bone marrow was flushed from the tibias and femurs of the donor MacGreen mice. After red blood cell lysis using the ACK lysis buffer, CD115+ cells were enriched by magnetically activated cell sorting using a CD115-biotin antibody and antibiotin microbeads (Miltenyi Biotec) according to the manufacturer’s instructions. After enrichment, monocyte purity was consistently 90%. A total of 103,106 enriched monocytes were transferred intravenously into mBSA-challenged AIP mice on day 1.

2.4. BrdU Pulsing. In steady-state BrdU kinetics experiments, mice were given three intraperitoneal injections of 2 mg BrdU (Sigma-Aldrich) 2 h apart, and BrdU labeling was monitored from days 1 to 5. For the short-term BrdU pulse, mice were injected intraperitoneally with 1 mg BrdU at 2–3 h before analysis. To assess BrdU incorporation, we stained, fixed, and permeabilized suspended cells using Cytofix/Cytoperm and Perm/Wash buffers (BD Pharmingen) according

![Image](https://example.com/image1.png)

**Figure 1:** (a) Intestinal epithelial tissue analyzed by TUNEL staining (apoptosis) and Ki67 immunohistochemical staining (proliferation). (b) Percentage of TUNEL-positive cells. (c) Percentage of Ki67-positive cells.
to the manufacturer’s instructions. Cells were incubated at 37°C for 60 min in 30 mg DNase (Sigma-Aldrich), stained with anti-BrdU-FITC for 30 min, washed, and analyzed by flow cytometry.

2.5. Statistical Analysis. Data were analyzed using SPSS 18.0 and GraphPad Prism 8.0 software. Data are means ± standard deviation. Student’s t-test was used to analyze differences in the mean values between two groups. A value of p < 0.05 was taken to indicate statistical significance.

3. Results

3.1. Effect of Piroxicam. The effects of macrophage deficiency on the apoptosis and proliferation of intestinal epithelial cells in Csf1<sup>op/op</sup> transgenic mice were determined by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay and Ki67 staining. Under normal conditions, the intestinal epithelium of Csf1<sup>op/op</sup> transgenic mice showed a higher apoptosis rate and lower proliferation rate than those of wild-type mice. In the presence of NSAIDs,
The intestinal epithelial cells in Csf1 op/op transgenic mice showed a higher apoptosis rate (27.80 ± 2.21 vs. 19.41 ± 3.28, p < 0.05) and lower proliferation rate (10.50 ± 1.30 vs. 16.88 ± 3.49, p < 0.05) compared with wild-type mice (Figure 1). Therefore, NSAIDs may cause gut dysfunction by damaging intestinal epithelial cells.

3.2. NSAIDs Promoted Intestinal Epithelial Permeability and Bacterial Translocation. Under normal conditions, the intestinal epithelium of Csf1 op/op transgenic mice showed higher inter- and paracellular permeabilities and bacterial translocation compared with that of wild-type mice. In the presence of NSAIDs, inter- and paracellular permeabilities of the intestinal epithelial cells were increased in Csf1 op/op transgenic mice but unaffected in wild-type mice (27.63 ± 3.23 vs. 21.90 ± 2.04, p < 0.05). The bacterial translocation rate was increased by NSAIDs in Csf1 op/op transgenic mice but unaffected in wild-type mice (Figure 2). In addition, Csf1 op/op transgenic mice had lower TJPs compared with wild-type mice under normal conditions and in the presence of NSAIDs. Therefore, NSAIDs promoted intestinal epithelial cell inter- and paracellular permeabilities and bacterial translocation in transgenic mice.

3.3. NSAIDs Reduced the Number of Mesenteric Lymph Nodes. Csf1 op/op transgenic mice had fewer mesenteric lymph nodes than wild-type mice under normal conditions (Figure 3). The number of mesenteric lymph nodes in Csf1 op/op transgenic mice was reduced by NSAIDs.

3.4. NSAIDs Decreased the Percentage of Activated T Cells. In the presence of NSAIDs, the percentage of activated T cells (CD4+CD44+) was significantly lower in Csf1 op/op transgenic mice than in wild-type mice (8.78% vs. 14.9%, p < 0.05, Figure 4).

3.5. NSAIDs Reduced the Percentage of CD4+Foxp3+ Cells. In the presence of NSAIDs, the number of memory T cells was significantly lower in Csf1 op/op transgenic mice than in wild-type mice (8.91 ± 2.11 vs. 14.85 ± 2.42, p < 0.05, Figure 5).

3.6. NSAIDs Suppressed Apoptosis of Caco-2 Cells. Intraductal intrinsic macrophages are the main source of GM-CSF under
normal conditions. To assess the effect of GM-CSF on the proliferation and apoptosis of intestinal epithelial cells, we formed the following four experimental groups: (1) normal conditions in Caco-2 and RAW264.7 cells, (2) LPS stimulation in Caco-2 and RAW264.7 cells, (3) normal conditions in Caco-2 cells and intestinal macrophages, and (4) LPS stimulation in Caco-2 cells and intestinal macrophages. We performed flow cytometry to evaluate the proportion of proliferating cells. LPS stimulated the secretion of GM-CSF by macrophages, which inhibited the apoptosis of RAW264.7 (4.77 ± 0.42 vs. 16.73 ± 1.31, p < 0.001) and intestinal (12.10 ± 2.38 vs. 20.37 ± 2.81, p < 0.01) macrophages (Figure 7).

3.8. GM-CSF Promoted Intestinal Epithelial Cell Proliferation. LPS stimulated the secretion of GM-CSF by macrophages, which promoted the proliferation of RAW264.7 (27.96 ± 4.76 vs. 8.55 ± 0.88, p < 0.001) and intestinal macrophages (22.10 ± 4.70 vs. 4.13 ± 1.40, p < 0.001, Figure 8).

3.9. GM-CSF Secreted by Macrophages Stimulated Invasion and Migration of Caco-2 Cells. We used a Transwell assay to assess the effect of LPS-stimulated intestinal macrophages and RAW264.7 macrophages on the permeability of intestinal epithelial cell monolayers. The results showed that macrophages directly secrete GM-CSF, stimulating invasion and migration by Caco-2 cells.

The levels of TJPs—closed bands (zonula occludens), JAM-A, and claudins—were measured by WB. GM-CSF regulated the epithelial cell barrier and promoted the synthesis of TJPs, maintaining intestinal barrier function (Figures 9 and 10).

4. Discussion

CSF1 and GM-CSF regulate the development and function of the mononuclear phagocyte system [11, 12]. We used Csf1<sup>op/op</sup> transgenic mice to explore the role of macrophages in NSAID-induced damage. The intestinal epithelial cells of Csf1<sup>op/op</sup> transgenic mice had higher apoptosis rates and lower proliferation rates. In mice deficient in CSF1, Paneth cells failed to develop, and the small intestine showed defects in cell proliferation and differentiation [13]. Macrophages also promoted maintenance of epithelial cells. Intestinal epithelial cells deficient in macrophages have lower TJP levels, resulting in higher inter- and paracellular permeabilities.
Figure 6: Apoptosis of Caco-2 cells determined by flow cytometry.

Figure 7: Proliferation of Caco-2 cells by flow cytometry.
Figure 8: GM-CSF promoted intestinal epithelial cell proliferation.

Figure 9: Levels of tight junction proteins.
and bacterial translocation. Because of the lack of macrophages, epithelial cells are more susceptible to NSAID-induced damage.

We also analyzed the molecular mechanisms underlying the regulation by GM-CSF of the mucosal barrier function. Macrophages directly secreted GM-CSF, promoting intestinal epithelial cell proliferation and inhibiting their apoptosis, thus maintaining intestinal barrier function. In NSAID-induced ileitis, macrophages are absent, which caused GM-CSF deficiency, increased apoptosis rates and inter- and paracellular permeabilities, and decreased proliferation rates, TJPs levels, numbers of mesenteric lymph nodes, memory T cells, and regulatory T cells in Csf1<sup>op/op</sup> transgenic mice.

GM-CSF is a pleiotropic cytokine that not only promotes the survival, proliferation, and differentiation of multiple hematopoietic cells after GM-CSF receptor binding but also plays an important role in immune regulation. GM-CSF enhances the acute reaction to bacteria (chemokine production, chemotaxis, adhesion, and phagocytosis) by activating monocytes/macrophages and neutrophils. It also stimulates the expression of Toll-like receptors 2 and 4 and regulates the response to lipopolysaccharide and peptidoglycan [9–11]. The mechanisms by which GM-CSF promotes the barrier function of the intestinal mucosa have only recently begun to be explored. GM-CSF signaling in nonhematopoietic cells regulates intestinal barrier integrity. The therapeutic effect of GM-CSF on patients with CD may therefore involve regulation of intestinal epithelial cell function.

GM-CSF plays an integral role in the response to injury of intestinal epithelial cells. Macrophages directly secrete GM-CSF, promoting the proliferation and inhibiting the apoptosis of intestinal epithelial cells. In addition, GM-CSF stimulates the invasion and migration of Caco-2 cells.

**Figure 10**: GM-CSF regulates the epithelial cell barrier and promotes the synthesis of tight junction proteins, maintaining intestinal barrier function.
5. Conclusion

GM-CSF is necessary for the barrier function of the intestine because macrophages directly secrete GM-CSF, promoting the proliferation and inhibiting the apoptosis of intestinal epithelial cells. In NSAID-induced ileitis, macrophage depletion increased the apoptosis rate and inter- and paracellular permeabilities and decreased the proliferation rate, TJPs levels, and numbers of mesenteric lymph nodes, memory T cells, and regulatory T cells in Csf1op/op transgenic mice. Therefore, GM-CSF is important for the recovery of macrophage deficiency.

Data Availability

Since our manuscript is an animal experiment, unavailable data cannot be released in the current study.

Conflicts of Interest

Conflict of interest statement is included without existing competing interests.

Authors’ Contributions

Xinxin Wang and Jiayang Wang contributed equally to this work.

Acknowledgments

This study was supported by the Beijing Nova Program (No. Z201100006820088); the Foundation of Beijing Anzhen Hospital, Capital Medical University (No. 2016Z01); the National Natural Science Foundation of China (Grant No. 81900098); the National Natural Science Foundation of China (Grant No. Z201100006820088); the Foundation of Beijing Anzhen Hospital, Capital Medical University (No. 2016Z01); the Foundation of Beijing Anzhen Hospital, Capital Medical University (No. Z201100006820088); the Foundation of Beijing Anzhen Hospital, Capital Medical University (No. Z201100006820088); and the Program of Organization Department of Beijing Municipal Administration of Hospitals (No. XMLX201822).

References

[1] J. Hampe, A. Franke, P. Rosenstiel et al., “A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1,” Nature Genetics, vol. 39, no. 2, pp. 207–211, 2007.
[2] J. D. Rioux, R. J. Xavier, K. D. Taylor et al., “Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis,” Nature Genetics, vol. 39, no. 5, pp. 596–604, 2007.
[3] A. P. Cuthbert, S. A. Fisher, M. M. Mirza et al., “The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease,” Gastroenterology, vol. 122, no. 4, pp. 867–874, 2002.
[4] K. S. Kobayashi, M. Chamaillard, Y. Ogura et al., “Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract,” Science, vol. 307, no. 5710, pp. 731–734, 2005.
[5] M. W. N. Harbord, D. J. B. Marks, A. Forbes, S. L. Bloom, R. M. Day, and A. W. Segal, “Impaired neutrophil chemotaxis in Crohn’s disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor,” Alimentary Pharmacology & Therapeutics, vol. 24, no. 4, pp. 651–660, 2006.
[6] M. J. Lodes, Y. Cong, C. O. Elson et al., “Bacterial flagellin is a dominant antigen in Crohn disease,” The Journal of Clinical Investigation, vol. 113, no. 9, pp. 1296–1306, 2004.
[7] P. Suenaeart, V. Bulteel, S. Vermeire, M. Noman, G. Van Assche, and P. Rutgeerts, “Hyperresponsiveness of the mucosal barrier in Crohn’s disease is not tumor necrosis factor-dependent,” Inflammatory Bowel Diseases, vol. 11, no. 7, pp. 667–673, 2005.
[8] K. Takeuchi, S. Smale, P. Premchand et al., “Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease,” Clinical Gastroenterology and Hepatology, vol. 4, no. 2, pp. 196–202, 2006.
[9] X. Han, K. Uchida, I. Jurickova et al., “Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn’s disease,” Gastroenterology, vol. 136, no. 4, pp. 1261–1271.e3, 2009.
[10] Y. Shibata, P. Y. Berczal, Z. C. Chrones, M. Yoshida, J. A. Whitsett, and B. C. Trappett, “GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1,” Immunity, vol. 15, no. 4, pp. 557–567, 2001.
[11] X. Han, S. Gilbert, K. Groschwitz et al., “Loss of GM-CSF signalling in non-haematopoietic cells increases NSAID ileal injury,” Gut, vol. 59, no. 8, pp. 1066–1078, 2010.
[12] C. Louis, A. D. Cook, D. Lacey et al., “Specific contributions of CSF-1 and GM-CSF to the dynamics of the mononuclear phagocyte system,” Journal of Immunology, vol. 195, no. 1, pp. 134–144, 2015.
[13] H. Fukuzawa, M. Sawada, T. Kayahara et al., “Identification of GM-CSF in Paneth cells using single-cell RT-PCR,” Biochemical and Biophysical Research Communications, vol. 312, no. 4, pp. 897–902, 2003.